Last reviewed · How we verify
TQH2929 Injections
At a glance
| Generic name | TQH2929 Injections |
|---|---|
| Sponsor | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Clinical Trial of TQH2929 Injection in Patients With Acute Flare-up of Generalized Pustular Psoriasis (PHASE2)
- A Clinical Study of TQH2929 Injection in Treatment With Generalized Pustular Psoriasis (GPP) (PHASE1)
- A Clinical Study of TQH2929 in Healthy Adult Subjects (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- TQH2929 Injections CI brief — competitive landscape report
- TQH2929 Injections updates RSS · CI watch RSS
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd. portfolio CI